Azir

Quick links to important sections

Azir

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azir

Quick Facts

Property Description
Active ingredient Azithromycin (as dihydrate)
Form Tablets, Capsules, Oral Suspension, Injection, Ophthalmic Solution
Pharmacological class Antibiotic (Azalide/Macrolide)
Common use Combating bacterial infections
Origin Semi-synthetic

What Type of Medicine is Azir (Azithromycin)?

Azir is a prescription-only medicine containing the single active ingredient Azithromycin, which is officially classified as an antibiotic. It specifically belongs to the Azalide subclass, distinguishing it within the larger family of Macrolide antibiotics. The compound Azithromycin is a semi-synthetic agent, chemically derived from the natural macrolide Erythromycin A, through a structural modification that influences its stability and absorption profile. This enhanced structure is clinically recognized for achieving effective concentrations in tissue, which contributes to its profile as a drug requiring less frequent dosing.

Composition and Forms of Azir

The drug contains Azithromycin (typically as the dihydrate) combined with various pharmaceutical excipients suited for the final product format. Azir is supplied in multiple common dosage form(s) to accommodate different therapeutic needs, including solid forms like tablets and capsules, liquid formulations such as oral suspension (prepared from powder), and preparations for intravenous injection. These forms are generally administered systemically (oral or IV) to treat internal infections, or, in the case of the ophthalmic solution, used for local treatment confined to the eye, offering therapeutic flexibility for various patient groups.

Azir's General Purpose as an Antibiotic

The primary general purpose of Azir is to help the body fight a wide array of susceptible bacterial infections. Its fundamental mechanism makes it a broad-spectrum agent that works by halting the growth and reproduction of the pathogen. Azithromycin is an effective agent for combating many common bacteria. This means the medicine is validated as a key tool for neutralizing pathogens and supporting the immune system's recovery process, often in scenarios where a short, manageable course of treatment is desired.

Regulatory References

  1. Azithromycin-containing medicinal products for systemic use - referral
  2. Azithromycin: MedlinePlus Drug Information

What side effects are possible with Azir?

Official Safety Profile and Adverse Reactions

The possible side effects and safety characteristics of Azir (Azithromycin) are formally documented by regulatory authorities, with adverse reactions categorized by frequency and affected body system. The most common effects listed include gastrointestinal disturbances such as diarrhea/loose stools, nausea, abdominal pain, and vomiting.


Serious and Clinically Significant Adverse Reactions

Official labeling specifically highlights the potential for rare but serious adverse reactions across several body systems. These serious risks, which are often classified as rare or frequency not known, include:

  • Cardiac Disorders: Prolongation of the QT interval with the risk of Torsades de pointes, a potentially fatal irregular heart rhythm.
  • Hepatobiliary Disorders: Severe, sometimes fatal, hepatotoxicity, including hepatic necrosis and hepatic failure.
  • Immune System/Skin Disorders: Severe hypersensitivity reactions such as Anaphylaxis, Stevens-Johnson Syndrome (SJS), and Toxic Epidermal Necrolysis (TEN).

Population-Specific Safety Considerations

The safety profile includes constraints for specific patient populations, as stated in official regulatory documents:

  • Hepatic and Renal Impairment: Caution is advised in severe renal impairment; use is contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior Azithromycin use.
  • Proarrhythmic Conditions: Use is restricted in individuals with known QT prolongation or other proarrhythmic conditions (e.g., clinically relevant bradycardia).
  • Older Adults and Neonates: Particular caution is advised for older adults due to increased cardiac risk, and a documented association exists with Infantile Hypertrophic Pyloric Stenosis (IHPS) in neonates.

Furthermore, safety information notes that certain post-antibiotic issues, such as Clostridioides difficile-Associated Diarrhea (CDAD), can be reported up to two months after treatment.

Overdose and Emergency Response

Azir overexposure is officially documented to present with intensified manifestations of known adverse effects, primarily affecting the gastrointestinal system. These symptoms include severe nausea, vomiting, and diarrhoea. Additionally, regulators document a specific potential auditory effect, noting cases of reversible loss of hearing following overexposure.

The most critical official risk involves the cardiovascular system. Overdose is strongly associated with prolongation of the heart's QT interval, which can escalate into Torsades de pointes, a potentially life-threatening ventricular arrhythmia. This severe cardiac risk necessitates a rapid response.

Regulatory authorities mandate that individuals must seek immediate medical attention if an overdose is suspected or confirmed. Urgent medical care is required for critical symptoms such as fainting, severe dizziness, collapse, or a fast or irregular heartbeat. Officially described management procedures emphasize symptomatic and supportive measures. There is no specific antidote known for Azithromycin overexposure. Management may involve the administration of medicinal charcoal, and continuous monitoring, including an ECG, may be indicated, especially for patients considered high-risk, such as the elderly or women, who are noted to have increased susceptibility to proarrhythmic effects.

Therapeutic Uses of Azir

What Azir Treats: Main Uses and Benefits

Azir (Azithromycin) is commonly used across several therapeutic domains to manage conditions characterized by periods of heightened symptoms associated with susceptible bacteria. The medication provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms. This medicine is relevant for easing symptoms related to a wide range of bacterial infections.


The medicine is applied across domains where additional symptomatic support is needed for infections of the respiratory tract, including pneumonia, bronchitis, and sinusitis; uncomplicated skin infections; and various sexually transmitted infections (STIs), such as chlamydia. It is commonly used when groups of symptoms appear suddenly or fluctuate, such as persistent cough, chest congestion, or severe sore throat. The medicine contributes to improved comfort during periods of heightened symptoms by assisting with maintaining functional stability.

“The medicine is commonly used to help with symptomatic relief in conditions marked by increased physiological stress.”

Specialized Use and Relief

Azir is also relevant in contexts marked by increased discomfort or tension, such as treating specific bacterial eye infections (e.g., trachoma). Furthermore, it may be part of symptomatic management to help manage the risks associated with certain opportunistic infections, like disseminated Mycobacterium avium complex (MAC) disease, in vulnerable patient groups. This application is relevant in contexts involving heightened systemic burden and contributes to helping patients cope more steadily with symptom fluctuations.

Quick Fact: Support for Acute Bacterial Symptoms
Primary Focus: Symptoms related to physical discomfort and inflammatory or irritative states.
Scenario: Applied in clinical settings that involve acute or unstable symptom patterns, such as sudden respiratory flares or localized inflammation.
Benefit: Supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Azir

The eligibility criteria for Azir (Azithromycin) are strictly defined by regulatory documents focusing on patient history and pre-existing conditions.


Contraindications (Absolute Prohibitions)

Azir is contraindicated and must not be used by any patient with a known hypersensitivity to azithromycin, erythromycin, or any macrolide or ketolide antibiotic. Use is also prohibited in individuals with a documented history of cholestatic jaundice or hepatic dysfunction linked to prior azithromycin therapy.


Established Use and Conditional Restrictions

Use is established for adults and pediatric patients generally ge 6 months of age, with specific indications cleared for children ge 2 years. Safety and effectiveness are not established for infants under six months.

Caution is required for specific populations, including:

  • Patients with severe hepatic impairment (use not recommended) or severe renal impairment (GFR < 10 mL/min).
  • Individuals with a history of QT prolongation or other proarrhythmic heart conditions.
  • Patients with myasthenia gravis, due to potential exacerbation of muscle weakness.
  • Pregnant or breastfeeding women, where use is allowed only after a clear risk-benefit assessment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes interactions officially documented in government regulatory sources, focusing strictly on specific substance combinations, pharmacokinetic outcomes, and administration rules.


Documented Pharmacokinetic and Pharmacodynamic Interactions

Azir (Azithromycin) has a low documented potential for metabolic interaction, as it is a poor inhibitor of the hepatic Cytochrome P450 enzyme system, distinguishing it from some other macrolides. However, it is an inhibitor of the P-glycoprotein (P-gp) efflux transporter. This transporter interaction can lead to increased serum concentrations of co-administered medicines that are P-gp substrates, such as Digoxin and Ciclosporin, necessitating monitoring of their plasma levels.

A key pharmacodynamic concern is the risk of QT interval prolongation. Co-administration with other QT-prolonging agents (e.g., Class IA and Class III Antiarrhythmics) requires heightened caution due to the documented risk of severe cardiac arrhythmia, specifically Torsades de Pointes. Co-administration with Warfarin requires careful monitoring of prothrombin time due to reports of altered coagulation effects. The use of Ergot derivatives is not recommended due to the theoretical risk of ergotism.


Administration-Timing and Exposure Constraints

The co-administration of oral Azir and aluminum- or magnesium-containing antacids results in a reduction of Azir's peak plasma concentration ( C max). To mitigate this, official labeling mandates that these antacids must be administered at least 1 hour before or 2 hours after Azir. The HIV protease inhibitor Nelfinavir is officially documented to significantly increase Azir's serum exposure when taken concurrently.

Mechanism of Action

Azir's action profile involves a dual mechanism: inhibition of bacterial growth and modulation of the host's inflammatory response.


Targeting Bacterial Protein Synthesis

Azir's primary mechanism involves the molecule entering susceptible bacteria and binding specifically to the 23S ribosomal RNA within the 50S ribosomal subunit. This interaction physically blocks the nascent peptide exit tunnel, which arrests the process of polypeptide chain elongation and prevents the pathogen from creating the essential proteins needed for replication and survival. This cascade leads to the cessation of bacterial growth (bacteriostasis), which results in a systemic reduction of viable bacterial load.


Modulating Host Inflammatory Signaling

A distinct secondary effect occurs in the host, where Azir is actively concentrated in immune cells like macrophages. Within these cells, the drug acts as a modulator by suppressing key intracellular signaling pathways (such as NF-κB). This action limits the overproduction and release of pro-inflammatory chemicals, which leads to the suppression of pro-inflammatory mediator release.


Mechanistic Constraints

The drug’s function is constrained by bacterial defense mechanisms. Effectiveness is neutralized if the bacteria possess efflux pumps (actively removing the drug) or ribosomal methylases (modifying the drug's binding site on the 50S subunit), which prevents the initiation of the inhibitory cascade.

Dosage and Administration Information

How Azir (Azithromycin) is Used: Official Administration Guidelines

Azir is administered according to standardized protocols that define the route, frequency, and total course duration. The medicine is officially available for oral intake (as tablets, capsules, or suspension), as a lyophilized powder for Intravenous (IV) infusion, and as a topical ophthalmic solution for local use.


Official Administration Protocols

Systemic use is structured primarily around once-daily dosing for a limited number of administrations. A common adult regimen involves a total course of 1500 mg, often administered as 500 mg on the first day followed by 250 mg daily on days 2 through 5. Alternatively, for certain infections, a single high dose of 1000 mg (1 g) is prescribed. Long-term use, such as for specific prophylaxis, involves a once-weekly schedule.


Administration Conditions and Preparation

Oral Forms: Immediate-release tablets and capsules may be taken with or without food. However, specific single-dose oral suspension formulations are typically instructed to be taken on an empty stomach (at least one hour before or two hours after a meal) to optimize absorption. If a dose is missed, it should be taken immediately, with the next dose scheduled 24 hours afterward.

Intravenous Use: The powder must be reconstituted and diluted prior to administration. The resulting solution must be administered only via slow IV infusion (drip) over a defined time, generally 60 minutes or longer, and is never given as a rapid bolus injection. Dosage in pediatric patients is officially calculated based on the child's body weight to determine the appropriate dose for the course.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Azir (Azithromycin)


Evidence from Short-Course Trials in Acute Infections

The research base reviewed for Azir's common acute indications includes short-term Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. Researchers have used these methods to study how Azir was examined in study settings for conditions like Community-Acquired Pneumonia, Acute Exacerbations of Chronic Bronchitis, and certain skin and soft tissue infections. These studies monitored high-level outcomes related to physical discomfort and systemic or functional imbalance, such as measuring clinical failure rates and how symptoms evolved in the observed populations.

For these short-course applications, studies monitored outcomes, and the findings describe patterns observed in the studied populations. Research provides insight into short-term changes by monitoring how outcomes linked to inflammatory or irritative states evolved. However, the results apply mainly to the specific populations studied, typically adults and children with mild to moderate infections. Follow-up durations were limited, meaning there is insufficient information for long-term outcomes.


Studies Addressing Chronic Conditions and Prophylactic Use

Research has also explored Azir in long-term observational settings for certain chronic respiratory conditions where symptoms may vary in intensity. For conditions such as COPD or bronchiectasis, long-term, placebo-controlled RCTs were conducted, monitoring outcomes related to episodic or acute changes such as tracking the frequency of symptomatic flare-ups.

Studies observed patterns related to specific adult populations with a history of recurrent exacerbations. However, long-term effects are not fully established. Researchers note that this extended exposure was associated with a reported increase in antimicrobial resistance within the observed populations. Therefore, the measurements observed in these long-term studies are assessed against the potential for developing resistance and the limited information available regarding long-term safety profiles.


Key Evidence Gaps and Areas of Uncertainty

Azir was evaluated in studies across different patient demographics, including pediatric patients and different disease severity groups. However, data for certain groups, such as those with complex comorbidities, remain insufficient. A central area of scientific scrutiny is the continuous assessment of Azir's use in the face of rising antimicrobial resistance, which may lower the certainty regarding clinical utility for certain pathogens over time. Findings describe group patterns, not personal outcomes, and evidence for certain specialized uses is limited.

Frequently Asked Questions (FAQ)

Common questions about Azir (FAQ)

Q: How quickly does Azir start working?

A: Official product information states that Azir is rapidly distributed from the bloodstream into the body’s tissues. The concentration in the blood typically peaks (reaches its highest level) approximately two hours after a single oral dose. This rapid distribution profile is considered when evaluating the medicine’s characteristic use.

Q: How long does Azir stay in the body?

A: According to regulatory data, Azir has a long elimination half-life, reported to be approximately 68 hours, or about 2 to 4 days. This means the active ingredient is slowly released from tissues over an extended period. This long-lasting presence is a factor related to its characteristic use in short course regimens.

Q: Does Azir interact with common pain relievers like ibuprofen?

A: Official regulatory documentation does not list a specific, direct interaction between Azir and common pain relievers like ibuprofen. Regulatory authorities consistently advise that a healthcare professional be aware of all concurrent medicines and products being used.

Q: Does Azir interact with alcohol?

A: Regulatory guidance suggests a healthcare provider should be consulted regarding the consumption of alcohol while using Azir. Alcohol may potentially worsen some of the medicine's common side effects, such as nausea or dizziness. Furthermore, consuming alcohol may generally interfere with the body's ability to recover from an infection.

Q: Does Azir cause weight gain or weight loss?

A: Weight changes are included in postmarketing reports compiled by regulatory authorities. Some reports have noted instances of 'rapid weight gain' or 'unusual weight loss.' Because these are postmarketing observations, the frequency of these effects is currently listed as not known.

Q: Is it common to feel tired while taking Azir?

A: Fatigue (tiredness) and somnolence (drowsiness) are reported as adverse reactions in official documents. While these are not listed among the most common effects, they are categorized as effects with an incidence that is less common or not specifically known.

Q: Can Azir affect my sleep?

A: Insomnia, which is defined as difficulty sleeping, is listed as an uncommon side effect in regulatory documents such as the European Summary of Product Characteristics (SmPC).

Q: Can Azir cause dizziness?

A: Official safety information includes dizziness and vertigo (a sensation of spinning) among the reported adverse reactions. Dizziness is sometimes categorized as a less common effect noted in clinical trials and postmarketing surveillance.

Q: Can I take Azir if I have diabetes?

A: Regulatory documents do not list diabetes as an absolute prohibition (contraindication) or a special precaution. This indicates that the medicine has been considered in trials involving people with diabetes, but the ultimate decision for use is based on the prescribing physician’s judgment.

Q: Is Azir a controlled substance?

A: Azir is an antibiotic and is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). Its official scheduling is 'None,' which is consistent with the drug not being classified as having abuse potential.

Q: What if I take too much Azir by mistake?

A: Official FDA labeling reports that adverse reactions experienced during accidental overdosage were similar to those seen when taking the medicine at the normal prescribed dose. Official guidance notes that if overdosage occurs, general symptomatic and supportive measures are indicated. Any instance of overdosage should be evaluated by a healthcare professional.

Q: Is Azir a habit-forming drug?

A: Azir is classified as an antibiotic, and regulatory authorities do not classify it as a scheduled substance. This classification reflects that Azir is not considered to have potential for abuse or habit formation.

Q: What kind of benefits can I expect from Azir?

A: The main function of Azir, according to official indications, is to treat specific bacterial infections such as certain types of bronchitis, pneumonia, and sexually transmitted diseases. The primary benefit is its ability to stop the growth and reproduction of susceptible bacteria, which supports the body in resolving the infection.

Q: Why is Azir sometimes prescribed 'off-label' (clarification of the concept)?

A: Off-label use is a term used when a medicine is prescribed for a condition, patient group, or dosage that has not been officially reviewed and approved by regulatory bodies like the FDA. For Azir, this refers to uses or patient groups that are not included in the officially approved drug labeling.

Q: Are there long-term side effects associated with Azir?

A: Studies involving the long-term use of Azir note an association with an increased risk of developing antimicrobial resistance in the observed populations. Furthermore, safety information notes that certain post-antibiotic issues, such as Clostridioides difficile-associated diarrhea (CDAD), have been reported to occur for a period of time after treatment has ended.

Q: How do I know if Azir is working for me?

A: Efficacy, or how well the medicine is working, is measured by the improvement or resolution of symptoms associated with the bacterial infection it is treating. This typically includes a reduction in symptoms like fever, cough, or pain related to the infection. This is part of the overall clinical picture that would be observed.

Q: Is Azir safe for older adults (seniors)?

A: Official documents advise that particular caution is recommended for older adults. This is due to a potential increased cardiac risk, specifically the development of Torsades de pointes, which is a type of irregular heart rhythm. Regulatory documents state that this increased risk is an essential consideration when evaluating the appropriateness of the treatment.

Q: Are there different strengths of the Azir tablet?

A: Azir is officially supplied in tablet form in different strengths. According to the FDA label, these strengths include 250 mg, 500 mg, and a 600 mg strength tablet.

Q: How is Azir usually packaged?

A: The packaging of Azir varies depending on the strength and dosage form. The official labeling shows that it may be supplied in bottles containing multiple tablets or as single-dose packets for the oral suspension.

Q: Does Azir interact with birth control pills?

A: According to available clinical consensus information, Azir is not documented to affect the efficacy of hormonal birth control pills.

Q: If I stop taking Azir, what happens?

A: Official guidance emphasizes the importance of completing the full prescribed course of treatment, even if symptoms begin to improve quickly. Completing the full course is considered necessary to help ensure the infection is fully resolved.

Q: Where can I find official information about Azir research?

A: Official drug labels (e.g., FDA, EMA) and safety communications from health authorities (e.g., TGA, FDA) are updated based on clinical trials and published research to reflect the latest information.

Q: Are the side effects of Azir temporary?

A: The exact duration for common side effects is not formally specified in regulatory documentation. however, in the rare cases of serious adverse reactions, such as drug-induced liver injury, reports indicate that recovery may occur within several weeks to months after the medicine is discontinued.

How should Azir be stored and disposed of?

How to Store and Dispose of Azir (Azithromycin)

Storage requirements for Azithromycin are defined by formulation to maintain stability. Tablets must be stored at controlled room temperature, between 20 C and 25 C. The oral suspension powder and the reconstituted liquid suspension must be stored at or below 30 C (86 F).

Stability and Handling

The standard reconstituted suspension is stable for 10 days. The single-dose suspension, however, is stable for only 12 hours and must not be refrigerated. The diluted intravenous solution is an exception, stable for up to 7 days under refrigeration. All formulations must be stored out of the sight and reach of children. Any remaining reconstituted oral suspension must be discarded after the designated stability period.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Azir found in:

A-Z Index: